Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.53 |
| ▸ | CNR2 | P34972 | 6/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677446 | 1.00 | CNR1 (0.53) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4681440 | 0.96 | CNR1 (0.56) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4677591 | 0.95 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4676765 | 0.87 | CNR1 (0.50) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4683481 | 0.87 | CNR1 (0.50) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4679000 | 0.86 | CNR1 (0.56) | CNR1CNR2CYP2C9GPR55 | |
| SCHEMBL4676951 | 0.85 | CNR1 (0.59) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4680422 | 0.85 | CNR1 (0.59) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4676549 | 0.84 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL4681583 | 0.82 | CNR1 (0.53) | CNR1CNR2ABCC4MLNRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638953-B1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | claimed |
| EP-1638953-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004111034-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | claimed |
| EP-1638953-B1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABCC4 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.